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ABSTRACT
In this thesis, hyaluronic acid based biomaterials are studied. The properties and
potential applications of these polymers are characterized and discussed.
In Chapter 1, biomaterials are introduced as well as hydrogels and nanogels.
Hyaluronic acid is highlighted as a remarkable bio-polymer. The overall objectives of my
research are also discussed.
Chapter 2 is focused around trials for utilizing graphene oxide as a nanomaterial
for controlling the drug release of an aromatic compound. Hyaluronic acid based hydrogels
were synthesized as a delivery vessel. The results of the drug release profiles are examined
and discussed.
A different direction is taken in Chapter 3. A nanogel is formed using hyaluronic
acid and a thermoresponsive polymer. The synthesis of the grafted polymer itself as well
as the nanogel are outlined and the characterization of each are discussed.
In Chapter 4, two methods for surface modification of virus particles are discussed.
In one approach, a boronic acid grafted hyaluronic acid polymer is synthesized and
characterized. In another approach, “click” chemistry is utilized as an alkyne-terminated
polymer is synthesized and characterized for conjugation with an azide-modified virus.
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CHAPTER 1: GENERAL INTRODUCTION
1.1.Biomaterials
Biomaterials can be defined as any matter or construct that is able to interact with
biological systems.1 These materials can be comprised of natural or synthetic components
and are generally used in medical applications to aid in healing after disease or injury.1
Polymers, metals, glass, and even living cells or tissue all can be used as components when
making a biomaterial. These components are often combined and reengineered into
coatings, films, gels, foams, or fabrics for biomedical use.1 Biomaterials are not only
biocompatible, but they are also often biodegradable. Some applications where
biomaterials are currently being used include drug delivery systems, tissue engineering,
biosensoring, imaging, and medical implants.1
1.2. Hyaluronic Acid

Figure 1.1. Structure of hyaluronic acid

1

A biopolymer which is being utilized in the field of biomaterials is hyaluronic acid
(HA). Hyaluronic acid is a naturally occurring glycosoaminoglycan consisting of
alternating N-acetyl-D-glucosamine and D-glucuronic acid units.2 HA is a major
component of the extracellular matrix and is also found in bodily fluids and connective
tissues. HA is responsible for playing a part in several vital roles in the body such as cell
differentiation, tissue hydration and lubrication, and nutrient diffusion.2,3 Due to HA’s
biocompatibility, biodegradability, and unique viscoelastic properties, HA has often been
used in drug delivery, tissue engineering, and cell encapsulation.2,3 Cross-linking HA with
copolymers provides the ability for the formation of hydrogel or nanogel networks.
1.3. Hydrogels and Nanogels
Hydrogels are three-dimensional networks comprised of cross-linked, water-soluble
polymers. A variety of crosslinking methods are currently being employed to synthesize
hydrogels

such

as

Michael-addition

reactions,

Schiff-base

formations,

and

photopolymerization.4 These hydrogel networks can be classified into two categories based
on the nature of the cross-linking: physical networks and chemical networks. Physical
networks are based upon non-covalent interactions such as hydrogen bonding, ionic
interactions, or hydrophobic interactions. On the other hand, chemical networks are held
together by covalent bonds formed from the polymer chains.4
Hydrogels are currently being used in a wide range of applications. Some of these
applications include pharmaceuticals, food additives, tissue engineering, drug delivery,
cellular encapsulation, biomedical implants, and biosensors5. Hydrogels have also been
recently used in the making of artificial muscles, contact lenses, wound dressings, and
super absorbent materials.5
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Nanogels are comprised of small, nanoscale sized hydrogel like materials on the
nanoscale range.6 A major advantage of nanoscale hydrogels is the ability to form
emulsions which can be systemically delivered to organs, tissues, and cells that are difficult
to reach. Another advantage of nanogels over bulk hydrogels include the ability for rapid
pharmacokinetics.6 Nanogels are globular particles, however, advances in new synthesis
strategies allows for different shapes.6 They are also capable of being designed to have a
core-shell or a core-shell-corona structure.
Due to the fact that these gels are highly swollen and can incorporate 30% wt. or more
of drugs or biological materials, nanogels have high loading capacities which is
advantageous in applications where cargo is needed to be entrapped and stabilized.6 The
cargo is held in place within the nanogel through either hydrophobic, electrostatic, or van
der Waals interactions or through chemical means such as covalent bonding. Recent
attention has been gained for nanogels in the field of drug delivery, diagnostics, imaging,
glucose sensing, and tissue engineering.6
1.4. Research Objectives
The first goal of this work was to create a hyaluronic acid based hydrogel using “click”
chemistry with controlled drug releasing abilities. Graphene oxide was employed to serve
as a nanomaterial to control drug release of an aromatic based drug.
The second goal of this work was to synthesize a thermoresponsive hyaluronic acid
based nanogel. This study first involved grafting poly-n-isopropylacrylamide (pNIPAM)
onto the backbone of a hyaluronic acid polymer, followed by the synthesis of the
corresponding nanogel.

3

The third goal of this work was to develop grafted biopolymers for the application of
encapsulation and delivery of the vaccinia virus (VACV). There were two methods: (1) to
synthesize HA-g-B(OH)2 for the linking to VACV via formation of a boronate ester on the
surface of VACV and (2) DBCO-pNIPAM to be used as a “smart” coating of the VACV
via “click” chemistry.
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CHAPTER 2: GRAPHENE OXIDE FOR CONTROLLED RELEASE
OF AROMATIC BASED DRUGS

2.1 Abstract
In this study, the goal was to confirm graphene oxide as a nanomaterial for controlled
drug delivery. A hyaluronic acid based hydrogel was synthesized and used as the delivery
vessel for the hydrophobic drug, resveratrol. Graphene oxide (GO) was incorporated into
the drug delivery system via π-π stacking. Drug release profiles were then studied.
2.2. Introduction
Due to its unique physical properties, biocompatibility, and biodegradability,
hyaluronic acid (HA) has recently been studied for the use in localized and controlled drug
delivery applications.2-3 HA hydrogels allow the loading of drugs due to porosity and
swelling, and the release of drugs depending on a diffusion coefficient of the small
molecule. These hydrogels still have limitations such as non-homogeneous loading of the
drug and burst drug release due to the high water content and large pore sizes of the
network. 3 These limitations drastically reduce the practical use of HA hydrogel-based drug
deliveries in the clinic setting.
In order to overcome the pharmacological limitations of HA hydrogel-based drug
deliveries, modifying the microstructure of the hydrogel,5 or incorporating nanoparticles
can be performed.

7

Recently, the introduction of nanoparticles for the purpose of

controlling drug release has gained a lot of attraction.7 Graphene oxide is a nanomaterial
5

whose structure and delocalized surface π electrons can be used for drug loading via π–π
stacking, electrostatic, or hydrophobic interactions.8
The delivery of hydrophilic drugs has been most studied because of their compatibility
with the hydrophilic hydrogel and the aqueous solvents.6 Thus, the loading capacity and
subsequent release are easy to be studied. Hydrophobic drugs, present a greater challenge.
Non-homogeneous drug loading and burst, or rapid, release are often observed.6 A previous
study utilizing an aromatic drug, Senexin A, showed successful incorporation of GO into
the HA system with controlled release of Senexin A.9 The interaction with SNX and GO
was via π-π stacking and H-bonding.9
Resveratrol (RSV) is another aromatic drug and is commonly cited as the main active
polyphenol in red wine.10 RSV is an antioxidant stimulates cell proliferation through
protection against protease enzymes, increase of fibroblast function, and increase of
collagen formation.10 However, resveratrol exhibits several drawbacks including poor
stability, low aqueous solubility, degradation to pH, light, and temperature. RSV also has
poor oral bioavailability and is extensively metabolized in the body.10
The goal of this study was to create a synergistic hydrogel system consisting of
hyaluronic acid, resveratrol, and graphene oxide for controlled drug release. HA serves as
the degradable biocompatible matrix to house the GO and drug conjugate through H
bonding. First, the nanocarrier was synthesized by adhering RSV to GO via π–π and
electrostatic interactions. Next, the in situ encapsulation of GO-RSV was performed with
HA-based hydrogel. The drug release test was then determined.

6

2.3. Experimental
2.3.1. Materials and Instrumentation
All chemicals were purchased from VWR, Sigma Aldrich, and Click Chemistry Tools,
LLC. 1H NMR spectra were recorded on a Brucker ARX300 spectrometer. UV−vis
spectrophotometry was done on a Nanodrop 2000.
2.3.2. Experimental Procedures
2.3.2.1.Preparation of Drug-Loaded Graphene Oxide
Resveratrol (RSV) (2 mg) and GO (2, 4, 6, 8 mg) were added to 2, 4, 6, and 8 mL
Kphos buffer respectively (pH 7.4) (sonicated together for 2 h) and stirred for 24 h at 4 °C
in darkness. The product (RSV-GO) was collected by centrifugation at 3000 rpm, 4 °C, for
20 minutes and washing with PBS until the supernatant became color free. The resulting
RSV-GO pellet was freeze-dried. UV-Vis was used to measure the amount of unbound
RSV at an absorbance of 306 nm from the supernatant. The measurements were performed
relative to a calibration curve recorded under identical conditions, which then allowed for
the drug loading efficiency to be estimated.
The RSV-loading efficiency was calculated as follows, where WfeedRSV is the loaded
amount of RSV and WfreeRSV is the amount of unbound RSV in the supernatant:
RSV-loading efficiency % = 100 (WfeedRSV−WfreeRSV)/ WfeedRSV
2.3.2.2.Characterization of Graphene Oxide and Drug-Loaded Graphene Oxide
GO and RSV-GO were characterized by UV−vis spectrophotometry (Nanodrop
2000), and Scanning Electron Microscope.
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2.3.2.3. Formation of Drug-Loaded Graphene HA hydrogels
Methacrylated modified HA polymer was first synthesized at approximately 50%
molar modification based on monomer unit (50DM MeHA) following previous reports.11
The RSV-GO was dispersed in 1x PBS at 0.1% w/v by sonication for 2 h. Next, the 50DM
MeHA was added into the GO-RSV suspension at concentration of 3%. Once the polymer
completely dissolved in GO-RSV mixture, 0.5 M dithiothreitol (DTT) was added into the
mixture to form the hybrid GO-HA-RSV hydrogel.
2.3.2.4. Drug Release
Hydrogels were formed as described in Section 2.3.2.3 and placed in 96-well plates
with 100 μL of release PBS, covering the hydrogel. The amount of released RSV in the
withdrawn PBS was determined by UV- vis spectra at 306 nm. The PBS was then removed
and replaced every 24 h at an equal volume. The drug release profiles were performed until
RSV no longer released. A standard curve of RSV concentration versus absorption peak
intensity (at 306 nm) was established before performing the RSV release.
2.4. Results and Discussion
2.4.1. Preparation of Drug-Loaded Graphene Oxide and Drug-Loaded Graphene HA
Hydrogels
The sub-microsized GO was created by further sonicating GO, providing a size range
around 500 nm to 10 µm, as verified by SEM imaging (Figure 2.1).
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Figure 2.1. Scanning electron micrograph (SEM) of the graphene oxide after sonication for 2 h.

The GO was then mixed with RSV at different weight ratios (Figure 2.2A) in PBS for 24
h at 4 °C to generate RSV-loaded GO (GO-RSV). RSV could attach to GO at different
loading ratios with almost 100% loading efficiency (Figure 2.2B).
The UV-Vis spectrum of GO-RSV showed the absorbance at both 230 and 306 nm,
which corresponded to the absorbance peaks of GO and RSV respectively (Figure 2.2C).
Lastly, the GO-RSV HA hydrogel was formed by mixing 3% of MeHA polymer with
0.1% of GO-RSV in PBS and adding DTT (Figure 2.3).

2.4.3. Drug Release of Resveratrol-Loaded Graphene HA Hydrogels
Next, an investigation took place to determine if RSV could be delivered and released
in a controlled fashion from the GO-HA hydrogels. It has been reported that drug release
from a GO nanocarrier depends multiple factors such as pH, GO sizes, and interactions
between drug and GO carriers.8
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Figure 2.2. Preparation and characterization of Resveratrol-loaded graphene oxide. (A) Schematic
illustrating the preparation of Resveratrol-loaded graphene oxide (GO-RSV). (B) . Loading
efficiency of RSV on to GO at different weight ratios (n = 3) (C) UV-Vis of GO, RSV, and GORSV.
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+

DTT
GO-RSV

GO-RSV-HA hydrogel

Figure 2.3. Schematic illustrating the synthesis of Resveratrol-loaded graphene HA hydrogels via
thiol–ene “click” reaction.

In this research, the release behavior of RSV from GO-RSV HA hydrogels was done
in PBS with pH 7.4, which represents normal physiological pH. The release of RSV
without GO from RSV-HA hydrogels was also studied. Figure 2.2A shows that the RSV
released from the RSV-HA hydrogels reached equilibrium within 6 h at concentration of
220 μM in PBS, while a concentration of 160 μM was achieved in GO-RSV HA hydrogels.
The release of RSV from both the RSV-HA and GO-RSV HA systems showed a burst
release followed by a maintained release (Figure 2.5B). The cumulative release of RSV
from RSV loaded HA-based hydrogels was also the same as the GO-RSV HA hydrogels.
Further, to optimize the release of RSV, increasing polymer weight percentage and
polymer molecular weight was performed. It was found that increasing the polymer weight
percentage and molecular weight could slightly slow down the drug release (shown in
Figure 2.5C). This is due to the fact that higher polymer weight percentage and higher
molecular weight can lead to a greater degree of entanglement within the hydrogel matrix,
further trapping GO-RSV to lead to an even slower release.
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Figure 2.4. RSV release profiles of Resveratrol-loaded graphene (GO-RSV) HA hydrogels. (A)
RSV release profiles of GO-RSV HA hydrogels compared to RSV loaded HA hydrogels in first 24
hours in PBS. The values expressed are means (n = 3) ± SD. (B) RSV cumulative release profiles
of GO-RSV HA hydrogels and RSV loaded HA hydrogels for 11 days in PBS. The values expressed
are means (n = 3) ± SD. (C) Influence of the HA molecular weight and percentage on RSV release
profiles of GO-RSV HA hydrogels in PBS. The values expressed are means (n = 3) ± SD.
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2.5. Conclusion
A GO hybridized HA hydrogel for drug delivery was created. The hydrogel could
control the release of RSV and could be tunable to provide different drug release rates by
varying the polymer molecular weight and density. This study revealed a novel interaction
of the of resveratrol with graphene oxide in HA based hydrogels, which could be used for
prolonged delivery of aromatic small molecule drugs.
A hybridized GO-HA hydrogel was created to study the controlled release of RSV.
The drug release profiles showed that the release of RSV could be slightly controlled using
GO. Varying the polymer molecular weight as well as the polymer density were also
investigated. Increasing the molecular weight and density of the polymer further retarded
the release of RSV.
In future work, varying the ratio of loaded GO:RSV could be studied in order to
further slow and tune the release of RSV. Biocompatibility studies of the GO-HA hydrogel
could also be performed as well as in vitro drug release profiles. These studies would help
confirm the novel interaction between GO and RSV and the controlled release of RSV. The
GO-HA hydrogels could then be used for controlled delivery of small aromatic molecules
for various applications.
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CHAPTER 3: THERMORESPONSIVE HYALURONIC ACID BASED
NANOGEL

3.1 Abstract
The purpose of this study was to design and synthesize “smart” nanogels that could be
utilized as biomaterials. A thermoresponsive polymer, poly-n-isopropylacrylamide
(pNIPAM) was grafted onto the backbone of the biopolymer, hyaluronic acid using
EDC/NHS coupling. Nanogels were then created using a sonication method. Both the
polymer and nanogels were successfully synthesized and characterized and a
thermoresponsive effect was observed.
3.2 Introduction
Modern nanocarrier systems include liposomes, nanogels, lipid or polymeric
nanoparticles, and microemulsions.6 These carrier systems can facilitate the movement of
cells, drugs, or other cargo. Recently, hydrophobic drugs have gained interest as cargo due
to improved pharmacokinetics due to improved solubility and stability.6
Nanogels, like nanoparticles, are able to protect drugs and can be easily administered.
Over the past few years, “smart” or stimuli-responsive (e.g. pH, specific ions, or
temperature) gel systems have gained interest due to the advantages such as tunable size,
porous structure, and large surface areas for bioconjugation. The “smart” nature of these
polymers have facilitated applications in fields such as medicine, technology, and
biomedicinal engineering.12
14

Among the most studied thermoresponsive polymers is poly(N-isopropyl)acrylamide
(pNIPAM). The lower critical solution temperature (LCST) of pNIPAM, or the
temperature at which the polymer will undergo a phase transition from a flexible solvated
to a more rigid unsolvated state, is 32 °C.13 Poly(N-isopropyl)acrylamide has a reversible
soluble-insoluble behavior because of the LCST. The phase change is a result from the heat
driven release of water molecules from the isopropyl side chains of pNIPAM. Above the
LCST temperature, the hydrophobic interactions increase, resulting in desolvation from the
aqueous phase.12
Grafting pNIPAM onto the backbone of hyaluronic acid not only creates a natural
biopolymer with thermoresponsive abilities, but it also presents an opportunity to tune the
LCST temperature of pNIPAM and thus, the gelling properties of the network.
3.3 Experimental
3.3.1

Materials and Instrumentation

All chemicals were purchased from VWR, Sigma Aldrich, and Click Chemistry Tools,
LLC. 1H NMR spectra were recorded on a Brucker ARX300 spectrometer. Nanogels were
prepared using a Fisher Scientific FS110D Ultrasonic Cleaner. The hydrodynamic radius
of the nanogel particles was determined using dynamic light scattering on a Zetasizer.
Nanogel particle size was also examined with Hitachi H-8000 scanning TEM operated at
an accelerating voltage of 200 kV. The particles were collected in 300 mesh copper grids
for imaging.
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3.3.2

Experimental Procedures

3.3.2.1 Synthesis of HA-g-pNIPAM Polymer
Hyaluronic acid (MW = 47kDa, 0.25 g based on monomer unit) was dissolved in
deionized water (50 mL). Next, EDC·HCl (0.506 g, 2.64 mmol) and Nhydroxysuccinimide (0.303 g, 2.64 mmol) were added to the solution. The pH was then
adjusted to 5.5 using 5 M HCl and the solution was stirred for 1 hour at room temperature.
Next, amine terminated poly(N-isopropyl)acrylamide (MW = 5.5 kDa, 0.181 g,3.30 x 10-5
mol) was added to the solution. The pH was adjusted to 7.5 using 5 M NaOH and the
reaction mixture was stirred for 48 hours at 4 °C. Dialysis was then performed against 1000
mL deionized water for 72 hours using dialysis tubing with MWCO = 10,000 g/mol. The
water was changed every 2 hours. Next, lyophilization was performed for 72 hours to
obtain the purified polymer.
3.3.2.2 Preparation of HA-g-pNIPAM Nanogels
The HA-pNIPAM nanogel was prepared using a sonication method in aqueous
conditions. A 0.5% w/v HA-pNIPAM solution in 1x PBS was then sonicated for 15
minutes on ice. The nanogels were allowed to settle overnight at 4 °C followed by 5 min
centrifugation at 3,000 g.
3.4. Results and Discussion
HA-g-pNIPAM was synthesized from HA polymer using EDC and NHS peptide
coupling with amine terminated pNIPAM. The amine-terminated pNIPAM was grafted
onto hyaluronic acid at 25% based on molar ratio corresponding to the disaccharide units.
Successful grafting of pNIPAM onto HA backbone was demonstrated through 1H-NMR
and TGA analysis.
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Figure 3.1. 1H NMR spectra of (top) hyaluronic acid, (middle) amine terminated poly(Nisopropyl)acrylamide, and (bottom) hyaluronic acid grafted poly(N-isopropyl)acrylamide.

Thermogravimetric analysis (TGA) was performed in order to establish the
composition of the HA-g-pNIPAM product. It was found that the degradation profile of
the grafted hyaluronic acid was different than that of the unmodified hyaluronic acid. The
initial degradation temperature of unmodified HA was around 233 °C, while the grafted
hyaluronic acid displayed two different degradation temperatures of 221 °C corresponding
to HA and 377 °C which corresponded with pNIPAM. The appearance of two degradation
temperatures for the grafted hyaluronic acid indicates the presence of two chemical
components within the polymer. Thus, the TGA could also demonstrate the successful
grafting of pNIPAM onto the backbone of HA.
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Figure 3.2. Thermal decomposition measured by thermogravimetric analysis (TGA) of (top) pure
HA and (bottom) HA-g-pNIPAM showing the successful grafting of hyaluronic acid.
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2.4. Preparation and Characterization of HA-g-pNIPAM Nanogels
Nanogels were prepared from HA-g-pNIPAM polymer through a sonication method
under aqueous conditions. Confirmation of the formation of nanogels was carried out
through differential light scattering (DLS) measurements and transmission electron
microscope (TEM) images.
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Figure 3.3. Particle size measured by dynamic light scattering (DLS) showing the thermoresponsiveness of the HA-pNIPAM nanogel. The significant change in size of naonogels indicated
the changes in polymer assembly at the lowest critical solution temperatures (LCST).

Particle size as well as the lower critical solution temperature (LCST) was measured
through DLS (Figure 3.3.). The thermoresponsive behavior of the polymer was also
observed through DLS. Below 20 °C, it was observed that the particles size was unstable.
The nanogel particles were in the hydrated state below 20 °C, which allowed for swelling
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and a larger size. Once the temperature reached 20 °C, the size of the nanogel decreased
and appeared to be stable, indicating the LCST had been reached. From 20 °C to 30 °C,
the hydrophobic interactions were increased as water was removed from the particles. The
nanogel particle size decreased as a result. Above 30 °C, the particle size increased
indicating the dissociation of the hydrogen bonding responsible for the nanogel formation.
TEM results confirmed the particle size of the nanogels as well as depicted a globular
morphology (Figure 3.4.). The nanogel particles measured to be approximately 300 nm
according to TEM.

A
A

B

Figure 3.4. Transmission electron micrograph (TEM) showing the morphology of the nanogel at
room temperature (25°C). Sizes measured by TEM were supported the measurements by DLS. (A)
TEM performed in 1x PBS. (B) TEM performed in 10x PBS.
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3.5. Conclusion
In this study, a thermoresponsive hyaluronic acid based nanogel was created. Poly-nisopropylacrylamide was first grafted onto hyaluronic acid using EDC/NHS coupling and
then the corresponding nanogels were formed. The thermoresponsive behavior of the
nanogels was then tested and observed.
Future research could involve cargo loading such as hydrophobic drugs. By loading
hydrophobic drugs into the HA-pNIPAM nanogel matrix, solubility issues could be
improved as well as potential enhanced drug loading. The thermoresponsive nature of
pNIPAM allows the nanogel to shrink in size when LCST is reached. The decrease in size
has been previously reported as the mechanism by which the hydrophobic drug could then
be released.13
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CHAPTER 4: GRAFTED HYALURONIC ACID BASED POLYMERS
FOR SURFACE MODIFICATION OF VIRUS PARTICLES
4.1 Abstract
In this study, the main goal was to synthesize biopolymers for the application of
encapsulation and delivery of envelope viruses. A boronic acid grafted hyaluronic acid
polymer was synthesized for the purpose of surface modification of the Vaccinia virus
(VACV) through boronate ester formation. A DBCO modified thermoresponsive polymer
was also synthesized so “click” chemistry could be performed to link the polymer to
VACV. Characterization of these polymers were also performed.
4.2 Introduction
The Vaccinia virus, formerly used as a vaccine in the eradication of smallpox, has
recently gained interest in a new light due to its oncolytic viral properties.17 Oncolytic
viruses are used in cancer therapy as they are designed to specifically target and replicate
within tumor cells, while not harming normal cells.17,18 The oncolytic viral agents are able
to both kill the tumor cells and provoke an immune response against the tumor cells.17,18 A
major issue facing virus based vaccines as well as viral agents is the storage and delivery
of these agents. Extreme temperature can damage and lead to viral death.34 Thus, a “coldchain” system is put into place from the site of manufacturing to the destination in order to
ensure that proper conditions are met during the storage, handling, and transport of
vaccines.34 One possible solution to overcome this issue is to increase the thermostability
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of the viral particles. Therefore, the goal of this study will be to modify the surface of
VACV in order to elicit increased thermostability of VACV. Specifically, this study will
aim to modify the surface of VACV by attaching “smart” coatings onto the virus composed
of poly(N-isopropyl)acrylamide (pNIPAM), phenylboronic acid, and hyaluronic acid. The
hypothesis is that by designing “smart” coatings consisting of biopolymers to encapsulate
the enveloped viral particles, the stability and infectivity can be tuned, which can present
solutions for a variety of applications.
An important feature of boronic acids are their ability to bond reversibly to diols to
form boronate esters.14 Five and six membered rings most likely form due to the prevalence
of 1,2-diols and 1,3-diols. This notable reaction has encouraged the studies of boronic acid
and polymers for the applications of self-regulated drug delivery systems, therapeutic
agents, and sensors for biological species, including saccharides and glycoproteins.14
Boronic acids appear to be non-toxic and have, therefore, been used in biomedical
applications.15
Delivery of VACV is a multi-faceted issue for oncolytic viral therapy. On one hand,
while systemic intravenous administration is easier than intratumoral injection, it presents
issues such as sequestration in the liver, nonimmune human serum, or anti-oncolytic virus
antibodies.19 On the other hand, virus neutralization can occur as a result of attack from the
immune system.19 Protection from virus neutralization as well as extended vascular
circulation has been achieved through coating the viruses in nanoparticles.20
Proteins, glycans, nucleic acids, and phospholipids are all sites of interest for chemical
modification on enveloped viruses.21-24 One method of linking agents such as fluorescent
probes to the envelope proteins of enveloped viruses is through modification of amino
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groups with various N-hydroxysuccinimide (NHS) esters.25 The introduction of azide tags
to viral proteins presents the use of the strain-promoted alkyne-azide cycloaddition
(SPAAC) reaction for a chemospecific site modification.
Another site for chemical conjugation is a glycan residue on the glycoprotein
structure. Specifically, vicinal diols are present in sugars that are able to bind to
phenylboronic acid (PBA) analogs.27 A recent study showed that the sialic acid present on
the glycoprotein of the vesicular stomatitis virus was efficiently labeled with quantum dots
conjugated with PBA.28 In this chapter, a PBA modified HA polymer was synthesized to
bind to the surface of VACV. Glycan residues can also be conjugated by adding azidosugars through metabolic incorporation followed by a SPAAC reaction with alkynecontaining molecules.29
Lastly, phospholipids are a site of modification among envelope viruses.
Modification on the lipid bilayer of the envelope have small effects on the biological
properties of viruses versus modification of another site. A point of interest is that due to
the fact that the viral envelope is composed of the cell membrane within host cells, the
modification of viral phospholipids can be achieved by hijacking the inherent phospholipid
biosynthesis.30 Previous research has previously demonstrated that the surface of the
measles virus could be modified with a number of functional groups through the metabolic
incorporation of azide groups to either the phospholipid layer or surface proteins.31,32 To
then confirm that the azide-MV could undergo chemical modification, the strain-promoted
alkyne-azide cycloaddition (SPAAC) reaction was exercised using dibenzylcyclooctyne
(DBCO)-based fluorescent dyes or quantum dots. In another section of this chapter, a
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DBCO-thermoresponsive polymer was synthesized to bind to an azide modified VACV
via SPAAC.

Polymer
Encapsulation

Vaccinia
Virus
(VACV)

Release

Polymer-g-VACV

Figure 4.1. Schematic showing polymer coating onto VACV followed by release.

4.3. Experimental
4.2.1

Materials and Instrumentation

All chemicals were purchased from VWR, Sigma Aldrich, and Click Chemistry Tools,
LLC. 1H NMR spectra were recorded on a Brucker ARX300 spectrometer.
4.2.2. Experimental Procedures
4.3.2.1. Synthesis of HA-g-B(OH)2 Polymer

Figure 4.2. Scheme of HA-g-B(OH)2 synthesis

Hyaluronic acid (MW = 47 kDa, 0.25 g based on monomer unit) was dissolved in
deionized water (13 mL). Next, EDC·HCl (0.13 g, 6.59 x 10-4 mol) and 3-
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aminophenylboronic acid (0.045 g, 3.30 x 10-4 mol) were added to the solution. The mixture
was stirred at room temperature for 24 h and then lyophilized to obtain the crude polymer.
2.4.1. Synthesis of DBCO-pNIPAM Polymer
Amine terminated pNIPAM (MW = 5.5 kDa, 0.100 g, 1.82 x 10-5 mol) and DBCONHS-ester (0.007 g, 1.82 x 10-5 mol) were dissolved in 4 mL dichloromethane. The
solution was stirred at room temperature for 12 hours. Next, the reaction mixture was
frozen in -80 °C freezer overnight, followed by lyophilization for 84 hours.
4.4.

Results and Discussion

HA-g-B(OH)2 was synthesized by grafting 3-aminophenylboronic acid (APBA) onto
HA using EDC/NHS peptide coupling. The grafted polymer was analyzed through 1HNMR. The phenyl peaks belonging to APBA appeared around 7 ppm, which confirmed the
successful grafting of APBA onto HA backbone.
DBCO-pNIPAM polymer was synthesized from DBCO-NHS-ester and pNIPAM-NH2
through the use of NHS conjugation and the formation of an amide bond. The product was
characterized by 1H-NMR. The introduction of the DBCO unit will allow for click
chemistry through the SPAAC reaction on the modified surface of VACV.
4.5.

Conclusion

Currently, HA-g-B(OH)2, where the boronic acid portion was obtained from 3aminophenylboronic acid (APBA), was grafted onto HA through EDC/NHS coupling via
the carboxylic acid unit on HA and the amine on the APBA. DBCO-pNIPAM was also
synthesized.

26

Figure 4.3. 1H NMR spectra of (top) 3-aminophenylboronic acid, (middle) hyaluronic acid, and
(bottom) phenylboronic acid modified hyaluronic acid.

In the future, research could involve attachment to the VACV and the investigation of
the resulting thermostability, infectivity, and structural integrity of VACV. Self-assembly
of biodegradable polymers will aid in the development of thermostable VACV particles by
providing a shield around VACV. The hypothesis is that the biopolymer coating or “shield”
will be able to protect the VACV particles and enhance its structural integrity and
thermostability to prevent the deformation that may ultimately lead to viral death.
As a first approach, phenylboronic acid can be used as the method to attach HA to the
surface of VACV. Specifically, HA-g-B(OH)2 can be used in the assembly study. The sialic
acid present on the envelope glycoprotein of VACV has been reported to bind to boronic
acid through the formation of boronate esters, which will provide an anchor to the VACV.25
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In order for release of VACV itself, the boronate ester bond is able to be cleaved by the
addition of fructose or glucose, resulting in the controlled release of VACVs. Lastly, the
use of HA allows for the enzyme, hyaluronidase, to aid in further degradation of the coating
for the purpose of the release of VACV particles.
The thermostability of VACV can be enhanced through surface modification of VACV
in order to develop “cold-chain” free delivery systems. Enhancing the thermostability will
provide a more obtainable and sustainable approach to vaccine distribution. A focus could
also be targeted and controlled delivery for oncolytic cancer therapy. Once the
thermostable VACV coatings are established, cancer secreting peptides can be inserted as
linkers into the polymer to be cleaved by enzymes, resulting in a targeted and controlled
delivery of VACV.
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